The economic burden of recurrence in elderly patients with completely resected, stage IIB/IIC or III melanoma: an analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database
Economic burden is higher in patients with versus without melanoma recurrence and patients with distant versus locoregional recurrence. There is a high unmet need for adjuvant therapies that may help to prevent or delay recurrence.
Authors
- Arun Kumar (ORCID: https://orcid.org/0000-0002-8800-0296)
- Mizuho Fukunaga‐Kalabis (ORCID: https://orcid.org/0000-0001-5699-6941)
- Rajeev Ayyagari (ORCID: https://orcid.org/0000-0003-0870-2309)
- Ruixuan Jiang (ORCID: https://orcid.org/0000-0003-1737-2989)
- Travis Wang (ORCID: https://orcid.org/0000-0002-1175-1884)
- Yue Liu (ORCID: https://orcid.org/0009-0004-3506-4976)
- Pangsibo Shen
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1080/13696998.2024.2403283
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00